

Arsenic trioxide

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion	Acute myeloid leukaemia with recurrent genetic abnormalities

Asparaginase

Section	Indications
Cytotoxic medicines - Parenteral > General injections > unspecified: 10000 IU in vial powder for injection - Powder for injection: 10 000 IU in vial.	Lymphoid leukaemia, not elsewhere classified Unspecified malignant neoplasms of unspecified sites

Azacitidine

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 100 mg in vial powder for injection	Myeloid leukaemia

Bendamustine

Section	Indications
Cytotoxic medicines Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL	Chronic lymphocytic leukaemia or small lymphocytic lymphoma Follicular lymphoma

Bleomycin

Section	Indications
Cytotoxic medicines Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)	Kaposi sarcoma of unspecified primary site Germ cell tumour of testis Other specified malignant neoplasms of the ovary Unspecified malignant neoplasms of unspecified sites Hodgkin lymphoma

Calcium folinate (leucovorin calcium)

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule ◦ Oral > Solid > tablet: 15 mg; 5 mg; 25 mg ◦ Oral > Solid: 15 mg tablet ◦ Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule	Burkitt lymphoma including Burkitt leukaemia Osteosarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of rectum Malignant neoplasm metastasis in large intestine Malignant neoplasms of colon Unspecified malignant neoplasms of unspecified sites Malignant trophoblastic neoplasms of placenta

Capecitabine

Section	Indications
Cytotoxic medicines ◦ Oral > Solid > tablet: 150 mg; 500 mg	Malignant neoplasms of rectum Malignant neoplasm metastasis in large intestine Malignant neoplasms of colon Other specified malignant neoplasms of breast

Carboplatin

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL

Indications

Other specified gliomas of brain

Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx

Malignant neoplasms of cervix uteri

Malignant neoplasms of hypopharynx

Malignant neoplasms of nasopharynx

Malignant neoplasms of oropharynx

Osteosarcoma of bone or articular cartilage of unspecified sites

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Malignant neoplasms of nasopharynx

Other specified carcinomas of ovary

Other specified malignant neoplasms of bronchus or lung

Malignant neoplasms of breast

Retinoblastoma

Malignant neoplasms of kidney, except renal pelvis

Chlorambucil

Section

Cytotoxic medicines

- Oral > Solid: 2 mg tablet

Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Unspecified malignant neoplasms of unspecified sites

Cisplatin

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 10 mg per 10 mL; 20 mg per 20 mL; 50 mg per 50 mL; 100 mg per 100 mL
- Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL
- Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection

Indications

Other specified gliomas of brain

Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx

Malignant neoplasms of cervix uteri

Malignant neoplasms of hypopharynx

Malignant neoplasms of oropharynx

Malignant neoplasms of nasopharynx

Germ cell tumour of testis

Osteosarcoma of bone or articular cartilage of unspecified sites

Other specified malignant neoplasms of the ovary

Malignant neoplasms of nasopharynx

Other specified malignant neoplasms of bronchus or lung

Unspecified malignant neoplasms of unspecified sites

Cladribine

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 1 mg per mL in 10 mL vial; 2 mg per mL in 5 mL vial

Indications

Langerhans cell histiocytosis

Cyclophosphamide

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection ◦ Oral > Solid > dosage form: 25 mg; 50 mg ◦ Oral > Solid: 25 mg tablet ◦ Parenteral > General injections > unspecified: 500 mg in vial powder for injection	- Diffuse large B-cell lymphoma, not otherwise specified - Chronic lymphocytic leukaemia or small lymphocytic lymphoma - Plasma cell myeloma - Burkitt lymphoma including Burkitt leukaemia - Lymphoid leukaemia, not elsewhere classified - Other specified gliomas of brain - Anaplastic large cell lymphoma, ALK-negative - Anaplastic large cell lymphoma, ALK-positive - Rhabdomyosarcoma primary site - Malignant neoplasms of breast - Other specified malignant neoplasms of breast - Unspecified malignant neoplasms of unspecified sites - Hodgkin lymphoma - Malignant trophoblastic neoplasms of placenta - Follicular lymphoma - Ewing sarcoma of bone or articular cartilage of unspecified sites - Malignant neoplasms of kidney, except renal pelvis

Cytarabine

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial ◦ Parenteral > General injections > unspecified: 100 mg in vial powder for injection	- Acute myeloid leukaemia with recurrent genetic abnormalities - Burkitt lymphoma including Burkitt leukaemia - Lymphoid leukaemia, not elsewhere classified - Myeloid leukaemia - Anaplastic large cell lymphoma, ALK-negative - Anaplastic large cell lymphoma, ALK-positive - Langerhans cell histiocytosis - Unspecified malignant neoplasms of unspecified sites

Dacarbazine

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection

Indications

Hodgkin lymphoma

Dactinomycin

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 500 µg in vial powder for injection

Indications

Rhabdomyosarcoma primary site

Unspecified malignant neoplasms of unspecified sites

Malignant trophoblastic neoplasms of placenta

Ewing sarcoma of bone or articular cartilage of unspecified sites

Malignant neoplasms of kidney, except renal pelvis

Daunorubicin

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

Lymphoid leukaemia, not elsewhere classified

Myeloid leukaemia

Docetaxel

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL

Indications

Malignant neoplasms of breast

Other specified malignant neoplasms of breast

Unspecified malignant neoplasms of unspecified sites

Malignant neoplasms of prostate

Doxorubicin

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride) ◦ Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)	Diffuse large B-cell lymphoma, not otherwise specified Plasma cell myeloma Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Rhabdomyosarcoma primary site Osteosarcoma of bone or articular cartilage of unspecified sites Kaposi sarcoma of unspecified primary site Malignant neoplasms of breast Other specified malignant neoplasms of breast Unspecified malignant neoplasms of unspecified sites Hodgkin lymphoma Follicular lymphoma Ewing sarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis

Doxorubicin (as pegylated liposomal)

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)	Kaposi sarcoma of unspecified primary site

Etoposide

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
- Oral > Solid: 100 mg capsule; 50 mg capsule
- Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule
- Oral > Solid: 100 mg capsule

Indications

Burkitt lymphoma including Burkitt leukaemia

Lymphoid leukaemia, not elsewhere classified

Myeloid leukaemia

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Germ cell tumour of testis

Osteosarcoma of bone or articular cartilage of unspecified sites

Other specified malignant neoplasms of the ovary

Other specified malignant neoplasms of bronchus or lung

Unspecified malignant neoplasms of unspecified sites

Hodgkin lymphoma

Malignant trophoblastic neoplasms of placenta

Retinoblastoma

Ewing sarcoma of bone or articular cartilage of unspecified sites

Malignant neoplasms of kidney, except renal pelvis

Fludarabine

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
- Oral > Solid: 10 mg tablet (fludarabine phosphate)

Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Fluorouracil

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg per mL in vial
- Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule

Indications

Malignant neoplasms of nasopharynx

Malignant neoplasms of rectum

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of breast

Malignant neoplasms of colon

Unspecified malignant neoplasms of unspecified sites

Gemcitabine

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection	Other specified carcinomas of ovary Other specified malignant neoplasms of bronchus or lung

Hydroxyurea (hydroxycarbamide)

Section	Indications
Cytotoxic medicines ◦ Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g ◦ Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg	Squamous cell carcinoma of oropharynx Chronic myeloid leukaemia, not elsewhere classified

Ifosfamide

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection ◦ Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection	Burkitt lymphoma including Burkitt leukaemia Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Rhabdomyosarcoma primary site Osteosarcoma of bone or articular cartilage of unspecified sites Germ cell tumour of testis Other specified malignant neoplasms of the ovary Unspecified malignant neoplasms of unspecified sites Ewing sarcoma of bone or articular cartilage of unspecified sites Malignant neoplasms of kidney, except renal pelvis

Irinotecan

Section	Indications
Cytotoxic medicines ◦ Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial	Rhabdomyosarcoma primary site Malignant neoplasm metastasis in large intestine Malignant neoplasms of kidney, except renal pelvis

Melphalan

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial powder for injection
- Oral > Solid: 2 mg

Indications

Plasma cell myeloma

Mercaptopurine

Section

Cytotoxic medicines

- Oral > Liquid: 20 mg per mL
- Oral > Solid: 50 mg tablet

Indications

Lymphoid leukaemia, not elsewhere classified

Acute myeloid leukaemia with recurrent genetic abnormalities

Langerhans cell histiocytosis

Unspecified malignant neoplasms of unspecified sites

Methotrexate

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection
- Oral > Solid: 2.5 mg (as sodium salt)
- Parenteral > General injections > IV: 50 mg in vial (as sodium salt)

Indications

Lymphoid leukaemia, not elsewhere classified

Acute myeloid leukaemia with recurrent genetic abnormalities

Burkitt lymphoma including Burkitt leukaemia

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Langerhans cell histiocytosis

Osteosarcoma of bone or articular cartilage of unspecified sites

Malignant neoplasms of breast

Unspecified malignant neoplasms of unspecified sites

Malignant trophoblastic neoplasms of placenta

Oxaliplatin

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial

Indications

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of colon

Paclitaxel

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 6 mg per mL

Indications

Malignant neoplasms of cervix uteri

Kaposi sarcoma of unspecified primary site

Other specified malignant neoplasms of the ovary

Malignant neoplasms of nasopharynx

Other specified carcinomas of ovary

Other specified malignant neoplasms of bronchus or lung

Other specified malignant neoplasms of breast

Malignant neoplasms of breast

Pegaspargase

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection

Indications

Lymphoid leukaemia, not elsewhere classified

Procarbazine

Section

Cytotoxic medicines

- Oral > Solid: 50 mg (as hydrochloride)
- Oral > Solid > capsule: 50 mg (as hydrochloride)

Indications

Unspecified malignant neoplasms of unspecified sites

Hodgkin lymphoma

Realgar-indigo naturalis formulation

Section

Cytotoxic medicines

- Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

Temozolomide

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 100 mg in vial powder for injection
- Oral > Solid > capsule: 5 mg; 20 mg; 100 mg; 140 mg; 180 mg; 250 mg

Indications

Other specified gliomas of brain

Neuroblastoma, NOS

Unspecified malignant neoplasms of unspecified sites

Ewing sarcoma of bone or articular cartilage of unspecified sites

Tioguanine

Section

Cytotoxic medicines

- Oral > Solid: 40 mg

Indications

Lymphoid leukaemia, not elsewhere classified

Vinblastine

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)
- Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)

Indications

Other specified gliomas of brain

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Langerhans cell histiocytosis

Kaposi sarcoma of unspecified primary site

Germ cell tumour of testis

Other specified malignant neoplasms of the ovary

Unspecified malignant neoplasms of unspecified sites

Hodgkin lymphoma

Vincristine

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)
- Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)

Indications

Other specified gliomas of brain

Diffuse large B-cell lymphoma, not otherwise specified

Burkitt lymphoma including Burkitt leukaemia

Lymphoid leukaemia, not elsewhere classified

Langerhans cell histiocytosis

Kaposi sarcoma of unspecified primary site

Rhabdomyosarcoma primary site

Hodgkin lymphoma

Unspecified malignant neoplasms of unspecified sites

Malignant trophoblastic neoplasms of placenta

Follicular lymphoma

Ewing sarcoma of bone or articular cartilage of unspecified sites

Retinoblastoma

Malignant neoplasms of kidney, except renal pelvis

Vinorelbine

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial
- Oral > Solid > capsule: 20 mg; 30 mg; 80 mg
- Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial

Indications

Rhabdomyosarcoma primary site

Other specified malignant neoplasms of bronchus or lung

Other specified malignant neoplasms of breast